{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-008307","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.520231+00:00","generated_at":"2026-06-18T00:47:57.469212+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pyxis Oncology doses first subject in Phase 1 trial of ADC PYX-201 for solid tumors","bullets":["First subject dosed in open-label, dose-escalation Phase 1 trial PYX-201-101; preliminary data expected early 2024.","PYX-201 targets EDB fibronectin, overexpressed in many solid tumors; minimal expression in normal adult tissues.","Trial enrolling patients with NSCLC, HR+ breast, ovarian, thyroid, pancreatic, sarcoma, hepatocellular, kidney cancers.","PYX-201 uses FACT platform licensed from Pfizer (2021) for site-specific conjugation and improved safety profile.","Dosing milestone marks transition of Pyxis Oncology to a clinical-stage company."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-008307","json":"https://secwatch.observer/filing/0000950170-23-008307.json","markdown":"https://secwatch.observer/filing/0000950170-23-008307.md","text":"https://secwatch.observer/filing/0000950170-23-008307.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023008307/0000950170-23-008307-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023008307/pyxs-20230316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:47:57.469212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}